Linglong Deng, Hannah Petrek, Mei-Juan Tu, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu. Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ Acta Pharmaceutica Sinica B 11 (2021) 3950–3965J. Acta Pharmaceutica Sinica B, 2023, 13(8): 3577-3578. DOI: 10.1016/j.apsb.2023.07.002
|
Citation:
|
Linglong Deng, Hannah Petrek, Mei-Juan Tu, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu. Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ Acta Pharmaceutica Sinica B 11 (2021) 3950–3965J. Acta Pharmaceutica Sinica B, 2023, 13(8): 3577-3578. DOI: 10.1016/j.apsb.2023.07.002
|
Linglong Deng, Hannah Petrek, Mei-Juan Tu, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu. Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ Acta Pharmaceutica Sinica B 11 (2021) 3950–3965J. Acta Pharmaceutica Sinica B, 2023, 13(8): 3577-3578. DOI: 10.1016/j.apsb.2023.07.002
|
Citation:
|
Linglong Deng, Hannah Petrek, Mei-Juan Tu, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu. Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ Acta Pharmaceutica Sinica B 11 (2021) 3950–3965J. Acta Pharmaceutica Sinica B, 2023, 13(8): 3577-3578. DOI: 10.1016/j.apsb.2023.07.002
|
DownLoad: